QIAGEN N.V. QGEN recently launched two new tools for designing and ordering custom solutions to support microbial analysis of bacterial, fungal and viral targets. These new tools should enable researchers to customize their assays and panels for use on the QIAcuity digital PCR (dPCR) system and any third-party next-generation sequencing (NGS) system. 

These customizable digital PCR assays will be available on QIAGEN’s GeneGlobe web portal. 

QGEN Stock’s Trend Following the News

Subsequent to the news, QGEN's share price moved south 5.2% to $41.47 in after-market trading yesterday. QIAGEN is gaining synergies from its continuous efforts in expanding its portfolio of dPCR assays, supporting laboratories in increasing their detection capabilities and improving their results. Henceforth, we expect the latest launch to motivate market sentiment in favor of QGEN in the upcoming days.

QIAGEN currently has a market capitalization of $9.72 billion. The company delivered an average earnings surprise of 3.52% in the trailing four quarters.

About QGEN’s Customized Digital PCR Assay Design Tools

The newly launched tools include the one for Custom dPCR Microbial Assays, which is a first-of-its-kind custom assay design tool that designs primers and probes for specific microbial targets of interest. It is tailored particularly for bacterial, fungal and viral targets. This design tool software is powered by a sophisticated and thoroughly tested algorithm, developed specifically for microbial applications. 

Another tool is the QIAseq xHYB Custom Microbial Panels that will help customers design their own NGS panels, overcoming the limitations of panels offered by other vendors. Its advanced algorithm enables researchers to design their assays against many whole genomes at once, allowing them to achieve the highest possible resolution in applications such as microbial detection.

Moreover, the new products make nanoplate dPCR suitable for even more microbial targets in applications ranging from wastewater testing to food production to analysis of human pathogens. 

Industry Prospects Favor QGEN

Per a report by BIS Research, the global digital PCR market was valued at $678.1 million in 2023 and is expected to grow $3.3 billion by 2034 at a compound annual growth rate (CAGR) of 15.7% over the period. Key factors driving market growth are the rising adoption of personalized medicine to screen and diagnose genetic disorders and technological advancements. 

Image Source: Zacks Investment Research

QGEN’s Recent Development Within dPCR Space

In September, the company added over 100 new validated QIAcuity digital PCR assays for cancer research, inherited genetic disorders, infectious disease surveillance and other applications. These newly launched cancer and microbial assays meet the level of quality, multiplexing capabilities, customization, precision and sensitivity associated with all QIAcuity products.

QGEN Stock Price Performance

In the past year, QGEN’s shares have risen 2.9% compared with the industry’s 3% growth.

QGEN’s Zacks Rank and Key Picks

The company currently carries a Zacks Rank #3 (Hold).

Some better-ranked stocks in the broader medical space are Haemonetics HAE, Penumbra PEN and ResMed RMD. While ResMed sports a Zacks Rank #1 (Strong Buy) at present, Haemonetics and Penumbra carry a Zacks Rank #2 (Buy) each. You can see the complete list of today’s Zacks #1 Rank stocks here.

Haemonetics has an earnings yield of 5.02% compared with the industry’s 1.18%. Its earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 19.39%. The company’s shares have risen 1.8% compared with the industry’s 23.1% growth in the past year. Estimates for HAE’s 2025 EPS have moved north 0.4% to $4.59 in the past 30 days. 

Estimates for Penumbra’s 2024 EPS have moved north 8.1% to $2.79 in the past 30 days. Shares of the company have surged 60.6% in the past year compared with the industry’s growth of 32.7%. PEN’s earnings surpassed estimates in three of the trailing four quarters and missed in one, delivering an average surprise of 10.54%.

Estimates for ResMed’s fiscal 2025 EPS have risen 2.7% in the past 30 days. Shares of the company have surged 86.3% in the past year compared with the industry’s 32.1% growth. RMD’s earnings surpassed estimates in each of the trailing four quarters, the average beat being 6.4%. In the last reported quarter, it delivered an earnings surprise of 8.4%.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

ResMed Inc. (RMD) : Free Stock Analysis Report

Haemonetics Corporation (HAE) : Free Stock Analysis Report

QIAGEN N.V. (QGEN) : Free Stock Analysis Report

Penumbra, Inc. (PEN) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research